Navigation Links
Crescendo Biologics Raises GBP4.5 million in Seed-Funding Led by Sofinnova Partners
Date:10/12/2009

CAMBRIDGE, England, October 12 /PRNewswire/ -- Crescendo Biologics ("Crescendo") today announces it has raised GBP4.5 million in a seed-funding round to advance the development of its fragment antibody technology platforms. The funding round was led by Sofinnova Partners, a Paris-based venture capital firm, with Aitua, Avlar BioVentures and the Rainbow Seed Fund also participating.

Crescendo brings together highly innovative in vivo and in vitro technology platforms invented by scientists at the Babraham Institute, including Dr Marianne Bruggemann, a pioneer in the development of human antibody transgenics, and Dr Mike Taussig, an expert in protein display and array systems. Crescendo's technology platforms will enable the Company to generate diverse, stable and optimised human heavy chain (VH) fragments, the smallest functional binding units of an antibody molecule. These fragments offer several advantages as starting points for the development of novel therapeutics: they can be administered topically by inhaled and oral routes as well as by injection; they provide great flexibility in format of the product, including bi-specific targeting; they are easy to manufacture and stable; and they have the potential to target binding sites inaccessible to conventional antibodies.

The Crescendo transgenic mouse platform has the potential to rapidly and predictably generate human VH fragments that have high affinity and solubility, and no requirement for humanisation. This is combined with a powerful in vitro ribosome display technology which offers significant advantages in antibody optimisation.

The seed funding will allow Crescendo to advance the development of these platforms and to initiate the development of proprietary therapeutics, following the appointment of the CSO, Dr Mike Romanos, who has extensive experience in biopharmaceutical R&D and played a pivotal role in building GlaxoSmithKline's antibody
'/>"/>

SOURCE Crescendo Biologics Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Avaxia Biologics Awarded Phase I SBIR Grant to Develop Antibody Therapeutic for Oral Mucositis
2. Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors
3. Mylan Announces Strategic Collaboration with Biocon to Enter the Global Generic Biologics Market
4. ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema
5. BioSpecifics Technologies Corp. Announces FDA Acceptance of Biologics License Application With Priority Review for XIAFLEX(TM) for the Treatment of Dupuytrens Disease
6. LaVoie Group Adds Bio-Surgery Company, Pegasus Biologics, to Its Life Sciences Agency Roster
7. Frost & Sullivan Recognizes ApaTechs Leadership in Orthopedic Biologics
8. Bone Biologics Announces UCB-1 (NELL-1) Bone Growth Protein Production Process With Aragen Biosciences
9. FDA Accepts Amgens Submission and Files Biologics License Application for Denosumab
10. Insmed Sells Follow-on Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million
11. Interface Biologics secures $5mm financing and appoints Thomas P. Reeves President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... IL (PRWEB) March 25, 2015 ... Symmetry® Top-Loading Balances and Analytical Balances to get ... expanded line of weighing balances from the trusted ... Toploading Balances increase your efficiency by providing ... variety of samples. Weighing modes include parts counting, ...
(Date:3/25/2015)... CORAL SPRINGS, Fla. , March 25, 2015 ... (HIT) strategy and management consulting firm, has launched ... reference publication to simplify tracking of ePrescribing regulatory ... "The ePrescribing regulatory landscape continues to ... offerings to deliver what the industry, and ultimately ...
(Date:3/25/2015)... HAGUE, Netherlands , March 25, 2015  EndoStim ... for chronic gastro-esophageal reflux disease (GERD) in the March ... Surgery . 2015; 157(3):556-567 ], establishing the long term ... The study included 25 patients with severe GERD ... prescribed daily proton pump inhibitor (PPI) medication for an ...
(Date:3/25/2015)... NEW YORK , March 25, 2015 ... has released today version 4 of Face2Gene, ... Novel Analysis from computers, as well as mobile devices. ... patterns of human malformations to present comprehensive and up-to-date ... the Annual Clinical Genetics Meeting, ACMG 2015, in ...
Breaking Biology Technology:New Economical Top-Loading and Analytical Symmetry Balances from Cole-Parmer 2Point-of-Care Partners Launches the ePrescribing State Law Capsule 2EndoStim LES Stimulation therapy demonstrates long term safety and efficacy results in treating reflux patients 2EndoStim LES Stimulation therapy demonstrates long term safety and efficacy results in treating reflux patients 3FDNA Releases a Multi-Platform Version of Face2Gene, a Genetic Search and Reference Solution at ACMG 2015 2
... ball-shaped structure that suggests several interesting possibilities for motion ... of electrons through a bucky ball in a transistor ... its center of mass. Moreover, since bucky balls look ... they may be useful as lubricants for use in ...
... Squibb,Company (NYSE: BMY ) announced today that ... approval of IXEMPRA(TM) (ixabepilone) as,monotherapy for the treatment ... in patients whose tumors are resistant or refractory,to ... granted,approval of IXEMPRA in combination with capecitabine for ...
... 16 MacroChem,(OTC Bulletin Board: MACM) will participate ... the Hilton New York on October 18 and ... outside the Sutton Room, throughout each day of,the ... DeLuccia, will provide a company overview, including discussion ...
Cached Biology Technology:Bouncing bucky balls 2FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer 2FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer 3FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer 4FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer 5FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer 6FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer 7MacroChem To Participate in PIPEs Conference October 18th and 19th in New York City 2MacroChem To Participate in PIPEs Conference October 18th and 19th in New York City 3
(Date:3/17/2015)... , March 17, 2015  MecklerMedia Corporation ... largest exhibition for service robots ever held in ... takes place on May 11-13, 2015 at the ... exhibitors for the event include: Acorn Product Development; ... EZ-Robot; Infranor; Kinova Robotics; Littler; NewBotic Corporation; Neya ...
(Date:3/12/2015)... -- IriTech, a leading iris based identity management technology ... Design Network, announced today that the Chief Minister ... MK2120U device during a launching event of Andhra Pradesh ... The iris scanner is manufactured by U.S. based ... India through its Indian partner, Biometronic Technology, ...
(Date:3/12/2015)... , March 12, 2015 ... standardized identity and access management (IAM) solution for ... schedule. With Beta System,s new IAM package, customers ... practices gleaned from multiple IAM implementations across different ... software as well as any necessary services and ...
Breaking Biology News(10 mins):MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 3Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2
... Dr. Ron Koder, assistant professor of physics at The City ... devised a novel method for producing an artificial protein capable ... recently awarded a three-year $1.3 million grant from the U.S. ... be administered to injured troops on the battlefield. "Engineered ...
... & Biotechnology News (GEN) recently co-sponsored a roundtable discussion ... in environment clean-up after manmade or natural disasters. "Gulf ... Impact and to Help in Remediation" was also sponsored ... of Massachusetts Boston, where the discussions took place. Part ...
... on hold until after 40, or even 45, will be ... there are associated risks for babies when postponing child-bearing, the ... Aviv University,s Sackler School of Medicine and the Hospital for ... in Israel, a country that supports in vitro fertilization (IVF) ...
Cached Biology News:CCNY professor gets grant to develop 'artificial blood' 2Rocking the cradle after 45 2
... mixture excluding l-[U-14C]methionine, 1.85 MBq, 50 ... sterilized. > 1.85 GBq/mg atom ... Mixture of Ala, Arg, Asp, ... Phe, Pro, Ser, Thr, Tyr and ...
The Spheroplast Kit contains qualified reagents for the preparation of yeast spheroplasts. The reagents have been optimized for use with Pichia pastoris and are guaranteed to generate 70% spheroplast...
...
...
Biology Products: